Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study.
To evaluate quality of life (QoL) 10 years after treatments for localised prostate cancer (LPCa) patients in comparison with aged-matched healthy controls.



LPCa patients diagnosed in 2001 were obtained from 11 French cancer registries. Controls were recruited among the general population and were matched to patients on age and geographic area. EORTC Quality of Life Questionnaire - Core 30 items, Expanded Prostate Cancer Index Composite, Hospital Anxiety and Depression Scale and Multidimensional Fatigue Inventory self-reported questionnaires were used to measure QoL, anxiety and fatigue. Patients were classified in three groups according to previous treatments: radical prostatectomy (RP), radiotherapy (RT) and radical prostatectomy and radiotherapy (RP+RT). The differences in QoL between patients and controls and according to treatment groups were evaluated.



There were 287 patients and 287 controls. There was no socio-demographic difference between patients and controls. Treatments were: RP (143), RT (78), PR+RT (33), baseline hormone therapy (49) and hormone therapy at the time of the study (34). Patients had similar levels of global QoL, anxiety, depression and fatigue as controls. They reported more urinary troubles (urinary function and incontinence) (p < 0.0001) and more sexual dysfunctions (p < 0.0001) than controls, whatever the treatment group. Worse bowel dysfunction was reported in patients treated by RT and RP+RT (p < 0.002). According to the treatments, RP groups had the worst urinary function and incontinence (p < 0.01), and reported more bowel bother when the treatment was combined with RT.



Even though patients reported similar global QoL as control 10 years after treatment, patients reported numerous urinary and sexual dysfunctions. Patients treated with RP+RT reported cumulative sequelae of both treatments.
Calvados General Tumor Registry, François Baclesse Cancer Center, Caen, France. Electronic address: clarisse.kerleau@orange.fr.
Clarisse
C
Kerleau
Calvados General Tumor Registry, François Baclesse Cancer Center, Caen, France; UMR 1086 « Cancers et Préventions », Inserm - University of Basse-Normandie, Caen, France.
Anne-Valérie
AV
Guizard
Tarn Cancer Registry, Albi, France; Claudius Regaud Institute, IUCT-O, Tarn Cancer Registry, Toulouse, France.
Laetitia
L
Daubisse-Marliac
UMR 1086 « Cancers et Préventions », Inserm - University of Basse-Normandie, Caen, France; Quality of Life in Oncology National Platform, France.
Natacha
N
Heutte
EA 3181, SFR-FED 4234, University of Franche Comté, France.
Mariette
M
Mercier
Claudius Regaud Institute, IUCT-O, Tarn Cancer Registry, Toulouse, France.
Pascale
P
Grosclaude
UMR 1086 « Cancers et Préventions », Inserm - University of Basse-Normandie, Caen, France; Department of Medical Oncology, François Baclesse Cancer Center, Caen, France; CHU Côte de Nacre, University of Basse-Normandie, Caen, France.
Florence
F
Joly
D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000523:psychology* / Q000628:therapy; D011788:Quality of Life; D012959:Socioeconomic Factors; D017741:Survivors / Q000523:psychology*
Localised prostate cancer; Long survivors; Population based study; Quality of life